Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Natural dietary compound naringin inhibits glioblastoma cancer neoangiogenesis

Fig. 2

In-vivo-anti-tumor activity of naringin given i.p. against s.c. Implantedhhumann malignant glioma. Naringin (120 mg/kg/day)8administration began 7 dayssbefore U-87 inoculation (chemopreventive effect) (a) or 3 daysaafter celliimplantation (therapeutic effect) into theeright flank of the nude athymic mice (b) and8the6injection was done again until the day of sacrifice. Dose-6dependent6inhibition of human6glioma cellss(U-87) and HUVEC proliferation by naringin was measured by MTT assay (c). Resultssrepresent the means of five mice inneach group anddare expressed as averageevolume (mm3) ± SEM. Daily average tumorrvolumes forreach group were6compared throughout6the experiment usingsStudent’s t-test. **p < 0.01

Back to article page